Nichola Warnecke
Nurse Practitioner · Lima, OHNPI 1376824086
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.5% of it on its own, with 34 other manufacturers making up the rest. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 853 payments — averaging $46.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Gilead$5K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$830
- Lucid Diagnostics Inc.$712
- plus $5K from 29 others
What the payments were for
- Consulting fees$2,0405%
- Speaking & faculty fees$20,70552%
- Travel & lodging$2,3016%
- Food & beverage$14,79537%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 226 | $24,545 |
| Gilead | 47 | $5,040 |
| Takeda Pharmaceuticals U.S.A., Inc. | 125 | $2,173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 136 | $1,867 |
| Johnson & Johnson | 28 | $830 |
| Lucid Diagnostics Inc. | 41 | $712 |
| E.r. Squibb & Sons, L.L.C. | 6 | $635 |
| Bristol Myers Squibb | 51 | $565 |
| QOL Medical, LLC | 27 | $549 |
| Ardelyx, Inc. | 24 | $482 |
| Nestle Healthcare Nutrition Inc. | 31 | $384 |
| Pfizer | 11 | $236 |
| Daiichi Sankyo Inc. | 12 | $194 |
| Sanofi | 9 | $187 |
| Evoke Pharma, Inc. | 7 | $157 |
| Merck | 10 | $143 |
| Aimmune Therapeutics, Inc. | 8 | $137 |
| Lilly USA, LLC | 5 | $105 |
| Regeneron | 1 | $103 |
| Celltrion USA Inc. | 7 | $103 |
| Ironwood Pharmaceuticals, Inc | 7 | $99 |
| Phathom Pharmaceuticals, Inc. | 5 | $90 |
| Madrigal Pharmaceuticals | 6 | $87 |
| Intercept Pharmaceuticals, Inc. | 1 | $85 |
| Ferring Pharmaceuticals Inc. | 3 | $82 |
| Organon | 6 | $70 |
| Redhill Biopharma Inc. | 2 | $48 |
| Braintree Laboratories, Inc. | 3 | $40 |
| Amgen | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Medtronic | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,884 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 31 | $101,198 |
| LinzessLinaclotide | 73 | $71,917 |
| ZenpepLipase/Protease/Amylase | 17 | $51,821 |
| Sucralfate | 185 | $12,910 |
| Dexlansoprazole DrDexlansoprazole | 45 | $8,516 |
| Pantoprazole Sodium | 418 | $6,962 |
| Mesalamine | 11 | $5,842 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 82 | $5,095 |
| MovantikNaloxegol Oxalate | 13 | $4,948 |
| Famotidine | 354 | $4,191 |
| Omeprazole | 328 | $4,065 |
| Ondansetron Hcl | 18 | $3,820 |
| Colestipol Hcl | 48 | $3,118 |
| Esomeprazole Magnesium | 78 | $2,924 |
| Mercaptopurine | 20 | $2,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,867 | $101,19831 claims |
| AbbVieLinzess | $24,545 | $71,91773 claims |
| Aimmune Therapeutics, Inc.Zenpep | $137 | $51,82117 claims |
| Redhill Biopharma Inc.Movantik | $48 | $4,94813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Lima
- Krystal UmfleetLima$11K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.